6 Spam-Free Article(s) Found
Sort:
Relevance
Like
Date
Filter:
7d
All
DeepLinks
Article Searches
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates https://www.zacks.com/stock/news/2267253/alkermes-alks-q1-earnings-revenues-fall-shy-of-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2267253 May 02, 2024 - Alkermes' (ALKS) earnings and revenues miss first-quarter 2024 estimates. However, revenues rise year over year on strong proprietary product sales.
Repligen (RGEN) Q1 Earnings Miss, Revenues Beat Estimates https://www.zacks.com/stock/news/2267231/repligen-rgen-q1-earnings-miss-revenues-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2267231 May 02, 2024 - Repligen's (RGEN) first-quarter 2024 earnings miss estimates while revenues beat the same.
Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat https://www.zacks.com/stock/news/2268089/puma-biotechnology-s-pbyi-q1-earnings-and-revenues-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-2268089 May 03, 2024 - Puma Biotechnology (PBYI) reports narrower-than-expected first-quarter 2024 loss. The company maintains its revenue guidance for 2024.
Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y https://www.zacks.com/stock/news/2267221/sarepta-srpt-q1-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2267221 May 02, 2024 - Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y https://www.zacks.com/stock/news/2267310/moderna-mrna-q1-earnings-beat-estimates-revenues-down-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2267310 May 02, 2024 - Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.
Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates https://www.zacks.com/stock/news/2267317/jazz-jazz-q1-earnings-sales-fall-short-of-estimates?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2267317 May 02, 2024 - Jazz's (JAZZ) first-quarter earnings and sales miss the mark. The company reaffirms its guidance for full-year 2024.

Pages: 1

Page 1